Based on the results of these two phase 2 clinical trials, the FDA granted approval to amivantamab for the treatment of patients with NSCLC expressing one of the two EGFR common mutations, in first-line settings and following resistance to osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.